From Phase 1 Screening to Commercial Strategy
As increasingly complex, poorly water-soluble molecules enter development, choosing an amorphous solid dispersion (ASD) technology based only on near-term needs can create costly challenges later. This overview examines why leading approaches, including spray drying, hot-melt extrusion, co-precipitation, and KinetiSol™, should be evaluated early and on a drug-specific basis. Through comprehensive screening, optimization, biopharmaceutical analysis, and…
Read MoreAustinPx Capabilities Overview
Join Dave Miller, Chief Scientific Officer at AustinPx, for an overview of the company’s integrated formulation development, analytical, and clinical manufacturing capabilities for complex oral drug programs. The webinar explores AustinPx’s data-driven approach to preformulation, bioavailability enhancement, dosage form development, and speed-to-clinic manufacturing, including its broad ASD technology toolkit and proprietary KinetiSol™ Technology. Real client…
Read More